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Abbreviations
ACE Angiotensin converting enzyme
ART Assisted reproductive technologies
ASI  Aortic size index
ASRM  American Society for Reproductive Medicine
BAV Bicuspid aortic valve
BSA Body surface area
C- Caesarean
ESC European Society of Cardiology
FBN1  Fibrillin 1 gene
HTAD  Heritable thoracic aortic disorders
IRAD International Registry of Aortic Dissections
IUGR Intrauterine growth retardation
LDS Loeys–Dietz syndrome
MAC Montalcino Aortic Consortium
MFS Marfan syndrome
PGD Preimplantation diagnosis
PND Prenatal diagnosis
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TAAD Thoracic aortic aneurysms and dissections
TAAs Thoracic aortic aneurysms
TAD Thoracic aortic dissection
TS Turner syndrome
vEDS  Vascular Ehlers–Danlos syndrome
VSMC  Vascular Smooth Muscle Cells
Key Facts
Incidence: Aortic aneurysm occurs in 9 per 100,000 patient-years and acute 
aortic dissection in 2.6–4.7 per 100,000 person-years.
Inheritance: Monogenetic aortic diseases are most commonly transmitted in 
an autosomal dominant way. Multifactorial disorders, such as atheroscle-
rosis and hypertension, may also be involved.
Medication: ACE inhibitors and angiotensin receptor blockers should be 
stopped or changed to α methyldopa or beta-blockers.
World Health Organization class: II/III when the aortic root diameter is 
<40 mm and class IV, when the aortic root diameter is >45 mm.
Risk of pregnancy: Elevated risk of dissection.
Life expectancy: Improved dramatically with appropriate follow-up and pro-
phylactic aortic root surgery for aortic dilatation, but it is still reduced. The 
role of prophylactic surgery before pregnancy is uncertain.
Key Management
Preconception: Transthoracic echocardiography for assessment of valvular 
function and aortic root diameters. CT or MRI of the aorta with prophylac-
tic surgery for women with Marfan syndrome and an aortic root diameter 
>45 mm and for women with Loeys–Dietz syndrome and an aortic root 
diameter >40 mm. Genetic counseling in all monogenetic aortopathies.
FU during pregnancy: Known gene mutation, but normal aortic diameters: 
check at 20 weeks with echo. Known gene mutation and dilated aorta or 
history of dissection four to eight weekly imaging of aorta during preg-
nancy and up to 6 months postpartum. CMR is safe after 12 weeks (gado-
linium contraindicated during pregnancy). Careful blood pressure 
monitoring and aggressive treatment of hypertension are mandatory.
Delivery: Aortic diameter <40 mm or <20 mm/m2 in Turner syndrome: vagi-
nal; between 40 and 45 mm class IIa indication for vaginal delivery and IIb 
for Caesarean (C-) section; aortic diameter >45 mm or >20 mm/m2 in 
Turner syndrome: C-section.
Postpartum: Image of aorta before discharge and at 6 weeks post-delivery. 
Increased risk until 6 months post-delivery; continue close surveillance 
until then. Beta-blockers and calcium channel blockers can be used safely 
during breastfeeding.
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12.1  The Condition
This chapter will cover disease related to aortic aneurysms and dissections. Aortic 
coarctation and aortic valve disease (including bicuspid aortic valve ( BAV)) will be 
covered elsewhere. For a correct understanding and interpretation of the disease, we 
will start with a description of the normal aorta.
12.1.1  The Normal Aorta
The aorta (Fig. 12.1) is the largest artery of the body, extending from the aortic 
valve to the bifurcation into the common iliac arteries. The aorta has two main 
functions: a conduit function, distributing oxygenated blood to the systemic cir-
culation, and a pressure control function, regulating systemic vascular resistance 
and cardiac output through baroreceptors located in the ascending aorta and aortic 
arch. Through its elasticity, the aorta functions as a passive pump creating an 
almost continuous peripheral blood flow, commonly known as “the Windkessel 
effect” [1].
Anatomically, the aorta is subdivided into four major segments: the ascending 
aorta – comprising the aortic root (including the annulus, sinuses of Valsalva, and 
sinotubular junction) – and the tubular ascending aorta, the aortic arch (segment 
of the aorta between the brachiocephalic artery and left subclavian artery), the 
descending thoracic aorta (extending from the isthmus between the origin of the 
left subclavian artery and ligamentum arteriosum to the diaphragm), and the 
descending abdominal aorta (extending from the diaphragm to the iliac bifurca-
tion) [2] (Fig. 12.1).
Normal diameters of the aorta vary according to the location (tapering down 
going from the ascending to the descending part) and according to the individual’s 
gender and body surface area (BSA). Irrespective of BSA, women tend to have 
smaller aortas than men [3, 4]. With age, the aortic diameter increases at all seg-
ments with an average increase of 1 mm per decade for the ascending and descend-
ing thoracic aorta [5].
The aortic wall is histologically composed of three layers: a thin inner tunica 
intima lined by the endothelium; a thick tunica media characterized by smooth mus-
cle cells embedded in an extracellular matrix and concentric sheets of elastic and 
collagen fibers, bordered by a lamina elastica interna and externa; and the outer 
tunica adventitia containing mainly  fibroblasts, collagen, vasa vasorum, and lym-
phatics [6].
The composition of the vessel wall varies according to the location: the 
abdominal aortic wall consists of fewer elastic lamellae, contains less structural 
proteins and has a lower elastin to collagen ratio when compared to the thoracic 
aorta [7].
12 Aortopathy
168
Brachiocephalic
artery Arch
Left subclavian
artery
Descending thoracic
aorta
Descending abdominal
aorta
Tubular ascending
aorta
Sinotubular
junction
Sinuses
of Valsalva
Annulus
Diaphragm
Aortic root
Ascending aorta
Fig. 12.1 Aortic anatomy
12.1.2  The Diseased Aorta
Although more diseases are recognized, the two main conditions that we will con-
sider in the scope of this chapter include aortic aneurysm and aortic dissection/
rupture – the latter being consequences of preceding aortic aneurysm in many cases. 
Aortic aneurysm is defined as a permanent localized or diffuse dilatation of the 
aorta to at least 1.5 times its normal caliber and may affect the aortic root, tubular 
ascending aorta, aortic arch, and descending thoracic or abdominal aorta [2, 8]. 
Since pregnancy-related aortopathy is most commonly located in the thoracic aortic 
segments [9], we will further focus on thoracic aortic aneurysms and dissections 
(TAAD).
Aortic aneurysms will only occasionally lead to symptoms, related to local pres-
sure, such as coughing, hoarseness, or swallowing difficulties. In most cases, how-
ever, thoracic aortic aneurysms (TAAs) will have an asymptomatic course and – if 
left undiagnosed or untreated – they can lead to dissection, an acute life-threatening 
event that is still associated with high mortality and morbidity rates. In thoracic 
aortic dissection (TAD), blood is diverted from its usual location within the lumen 
of the aorta into a false lumen within the media through a tear in the intima. The 
dissection can subsequently propagate both proximal and distal to the tear, hence 
affecting vital branching arteries and leading to coronary, cerebral, spinal, and/or 
visceral ischemia. Several classification systems for TAD exist, of which the 
Stanford classification is the most widely used. In Stanford type A dissection, the 
ascending aorta is involved, whereas type B dissection is typically located distally 
from the left subclavian artery. The distinction between both subtypes is relevant in 
view of important differences in prognosis and management. In aortic rupture, the 
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tear in the aortic wall extends through all vessel layers, leading to life-threatening 
intrathoracic hemorrhage.
Due to its asymptomatic course, the exact incidence of thoracic aortic aneu-
rysms is largely unknown. A recent contemporary, prospective cohort study of 
middle- aged individuals in Sweden reported an incidence rate of 9 per 100,000 
patient- years (95 % CI 6.8–12.6) [10]. Estimating the incidence of acute aortic 
dissection is somewhat easier and has been studied more widely, but one has to 
bear in mind that a substantial proportion of aortic dissections may be left undiag-
nosed due to the high acute mortality rate of the disease. The incidence in the 
general population ranges from 2.6 to 4.7 per 100,000 person-years [11, 12]. The 
mortality rate associated with TAD reported a decade ago from the large 
International Registry of Aortic Dissections (IRAD) indicated that without urgent 
surgical intervention, type A dissection is associated with mortality rates as high 
as 20 % by 24 h and 40 % by day 7 [13]. Type B aortic dissections generally have 
a better outcome with a 30-day mortality rate of 10 %. Uncomplicated type B dis-
sections are conventionally treated medically, whereas complicated type B dissec-
tions are treated using endovascular techniques or open surgery – results being 
comparable according to recent studies [14]. Despite advances in medical and 
surgical treatment options, mortality rates remain high, as demonstrated in a more 
recent prospective cohort study where the acute and in-hospital mortality was 
39 % for aortic dissection and 41 % for ruptured TAD [10]. Women with aortic 
dissection typically present at an older age compared to men and display a higher 
hospital mortality and worse surgical outcome [15]. Etiological factors underly-
ing TAAD include conventional cardiovascular risk factors although the lack of 
any significant association of TAA or AD with trends in smoking prevalence in a 
recent epidemiological study may suggest a difference in etiology compared with 
abdominal aortic aneurysms [8]. Differences in the pathogenesis of thoracic and 
abdominal aortic aneurysms may result from differences in aortic structures, bio-
chemical properties, and origin of the vascular smooth muscle cells (VSMC) [16].
The underlying pathophysiology of TAAD has been widely studied, and many 
new insights have emerged from the study of monogenetic aortic diseases. These 
disease entities will be discussed in more detail below. Through human and mouse 
studies of monogenetic aortic diseases, it is now increasingly clear that aneurysms 
and dissections may result from alterations in structural, functional, and signal 
transduction properties in the wall of the aorta. The ensemble of these processes is 
referred to as altered mechanobiology and is illustrated in Fig. 12.2 and nicely 
reviewed by Humphrey and colleagues [46]. Based on these concepts, it is easy to 
conceive that dissections can be triggered by abnormalities in any of these pro-
cesses: altered mechanical factors (hypertension, increased cardiac output, increased 
wall shear stress), alterations in structural components of the aortic wall (genetic 
defects in components of the elastic fibers), alterations in the signaling pathway 
(genetic defects in any component such as the TGFβ pathway), or altered signal 
transduction (genetic defects in extracellular matrix components, intracellular 
receptors, modulators).
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12.2  Pregnancy Outcomes
Since the first report on pregnancy-related aortic dissection in 1944 [47], over 80 
additional reports have been published, most of them being case reports. A limited 
number of population-based studies and surgical series on the occurrence of aortic 
dissection have also been published, but caution is warranted when interpreting 
these results because of their heterogeneity with regard to design, study population, 
and diseases under study (type A vs. type B dissection).
Although the estimated incidence of aortic dissection during pregnancy is rela-
tively low (0.05–1.39 per 100,000 person-years [48, 49] or 0.6 % per pregnancy 
[15]), the high maternal mortality rates (between 21 and 53 %) account for the high 
ranking in the list of maternal death causes [48, 50–52]. The reported figures show 
some variation according to the country they are issued from. Aortic dissection 
ranks first on the list of mortality causes in the UK and the Netherlands, but is only 
the third cause of cardiovascular death in the French registry where three fatal dis-
sections are reported during the period of 2007–2009, two out of these three being 
in women with Turner syndrome [53].
Hormonal effects
on elastic fibers
Aorta
Mechanical force
Molecular response
Altered
hemodynamics
VSMC
Adaptive
remodelling
Actin
Adaptors
Myosin
Fibrillin-microfibril
LTBP
Elastin
Elastic fiber
Im
po
se
d
Me
ch
an
ica
l fo
rce
TGFβ
TGFβRI/2 complex
Cell membrane
SKI
Extracellular
matrix
Smad4
Smad3
Nucleus
ERK
ppp
p
p
p p p p
p38 JNK
Smad3
R-smadSmad4
Se
ns
ed
Me
ch
an
ica
l fo
rce
Integrins
Contractile cytoskeleton
MYH11
ACTA2
MYLK
PRKG1
FLNA
Extracellular matrix
FBN1
COL3A1
FBLN4
ELN
MFAP5
TGFβ signalling
TGFBR1
TGFBR2
SMAD3
SMAD4
TGFb2
TGFb3
SKI
Fig. 12.2 Concept of mechanobiology underlying homeostasis in the thoracic aorta and the pos-
sible effects of pregnancy. Mechanical force is sensed in the aortic wall and transmitted through the 
extracellular matrix to the intracellular molecular level. The signal is sensed by the smooth muscle 
cell contractile apparatus as well as by components of the TGFβ signaling pathway. Pregnancy 
affects the mechanical stimulus on the one hand and the elastic fibers in the extracellular matrix on 
the other hand. Alterations, either due to higher imposed forces (hypertension) or due to (genetic) 
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may lead to aneurysms/dissections. Genes involved in these pathways are listed at the bottom of 
the figure and are reported in Table 12.1 with their respective disorders
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In women younger than 40 years of age, pregnancy has reportedly been associ-
ated with a significant increase in the risk for acute aortic dissection (with odds 
ratios for pregnancy up to 23 in one study [49]. Other studies however could not 
demonstrate a direct link between dissection and pregnancy [48]. A selective report-
ing bias may be invoked as a possible explanation for these discrepancies [54]. 
These data should be interpreted carefully, especially in women with underlying 
conditions, until large prospective studies assessing all aspects of a direct link are 
published. Data on aortic disease extracted from the large international registry on 
the outcome of pregnancy in patients with congenital heart disease are expected to 
be very valuable (the ROPAC study, see for more information at http://www.escar-
dio.org/Guidelines-&-Education/Trials-and-Registries/Observational-registries- 
programme/Registry-Of-Pregnancy-And-Cardiac-disease-ROPAC).
The risk for aortic dissection during pregnancy increases with gestational age, 
with most of the events occurring during the third trimester (55–78 %) [51, 55]. The 
majority of reported aortic dissections occurring during pregnancy (70 %) are type 
A aortic dissections [9], although type B aortic dissections seem to be more com-
monly reported in women with Marfan syndrome (see below).
In addition to the hemodynamic and hormonal changes occurring during preg-
nancy, the process of labor imposes substantial stress on the aorta and, hence, 
increases the risk for dissection. Uterine contractions, pain, stress, exertion, and 
bleeding, all impose an extra demand on the cardiovascular system [56]. The correct 
management of women at increased risk for dissection during labor in an experi-
enced fetomaternal unit is, therefore, mandatory [57]. Follow-up of the aortic diam-
eter and awareness of a possibly higher risk of aortic dissection should be considered 
until 6 months postpartum [51].
12.2.1  Predisposing Conditions
Several diseases are associated with increased aortic vulnerability, and affected 
women will therefore require special multidisciplinary care starting before preg-
nancy and extending well after delivery.
12.2.2  Heritable Thoracic Aortic Disorders: H-TAD
H-TAD is a heterogeneous group of disorders characterized by the common denom-
inator of thoracic aortic disease (TAD) [58]. The presentation of aortic involvement 
varies widely from an incidental finding on an imaging study to fatal aortic dissec-
tion. The term “heritable” does not necessarily imply that all these disorders have a 
known genetic cause – despite significant advances in the genetic background of 
TAD, many patients and families do not harbor mutations in the genes identified so 
far. Based on the presence of additional clinical features in other organ systems, 
H-TAD can be further subdivided into syndromic and nonsyndromic forms. The 
spectrum of genes identified in these various clinical entities is highly variable. 
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Genes can be grouped in those encoding components of the extracellular matrix, 
genes encoding components of the TGFβ signaling pathway, and genes encoding 
components of the  VSMC contractile apparatus. An overview of the clinical condi-
tions according to the currently known genetic defects with their respective typical 
clinical characteristics is provided in Table 12.1. Nearly all genes listed in this table 
can also be identified in patients with nonsyndromic forms of H-TAD.
12.2.3  Marfan Syndrome
Marfan syndrome (MFS) is the prototype of syndromic H-TAD. MFS is caused by 
mutations in the fibrillin 1 gene (FBN1) and typically affects a myriad of organ 
systems including the ocular, the skeletal, and the cardiovascular systems. The clini-
cal presentation is highly variable, both within and between families [17–19, 59]. 
When considering the cardiovascular system, aortic aneurysms and dissections are 
the most common and life-threatening problems related to MFS. The risk for aortic 
dissection in MFS is significantly increased to 170 per 100,000 individuals per year 
(compared to 6 per 100,00 per year in the general population) [60]. Other cardiovas-
cular manifestations related to MFS include mitral valve prolapse, subclinical car-
diomyopathy, and arrhythmias [20, 61–65].
The intrinsic aortic wall fragility associated with MFS along with the hemody-
namic and hormonal changes occurring during pregnancy, as described above, gives 
rise to a higher risk for (fatal) dissection and aortic rupture in pregnant MFS women. 
Early publications, mostly case reports, on pregnancy in MFS showed a grim out-
come with more than half of the cases ending with (fatal) aortic dissection. Most of 
the women in these earlier publications had preexistent severe cardiovascular dis-
ease, but based on these reports, patients were generally counseled against preg-
nancy [66]. A systematic assessment of pregnancy in MFS women was undertaken 
for the first time in 1981. Pyeritz and colleagues reviewed pregnancy-related cardio-
vascular risks in 26 patients with MFS and compared these to non-MFS women. 
Cardiovascular complications were not significantly different between both groups, 
but MFS women showed a higher rate of spontaneous abortion. Although no aortic 
diameters are reported in this study, the authors proposed an aortic root diameter of 
40 mm before pregnancy as a threshold for stratifying women as having low risk 
(1 %) or increased risk (10 %) for dissection. Since then this stratification has been 
widely applied and debated in the literature [9, 67–71], but remains a reference 
value in the current European guidelines for the management of cardiovascular dis-
eases during pregnancy [55]. In these guidelines the modified WHO classification is 
applied to determine maternal risk, where MFS patients may fall under class II to 
IV: women with no aortic dilation are classified as WHO II, women with an aortic 
dilation between 40 and 45 mm are classified as WHO III, and women with an aortic 
diameter above 45 mm are classified as WHO IV.
The risk of aortic complications in MFS is not only present during pregnancy and 
delivery but also during the puerperium and even beyond pregnancy. Indeed the 
concerns about the long-term effect of pregnancy on aortic root growth, the 
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incidence of dissection, and the need for elective aortic root replacement have been 
raised and need further assessment [72, 73].
Between 1995 and 2013, four prospective trials addressing pregnancy-related 
cardiovascular complications in MFS patients have been conducted – the main find-
ings on pregnancy outcome in these women are illustrated in Fig. 12.3. A total of 97 
women undergoing 149 pregnancies have been followed prospectively. Forty-two 
women in this combined cohort had an aortic root exceeding 40 mm prior to preg-
nancy, and five had undergone aortic root surgery prior to pregnancy [72, 74–76].
Three out of these four studies not only assessed the immediate effect of preg-
nancy but also looked at cardiovascular effects on the longer term [72, 74, 75]. A 
significant aortic root growth associated with pregnancy was observed in only one 
study (3 mm per pregnancy – interquartile range 0–7 mm). Aortic dissection was 
reported in a small subset of five women (Fig. 12.3). Type B aortic dissection was 
seen in four out of five cases. Although the latter observation warrants caution when 
advising patients to undergo elective surgery prior to pregnancy, large-scale studies 
are needed to confirm these findings. Also of note when interpreting these data is 
that in older cohorts (two out of these four studies [74, 75]), patients with other, 
more aggressive aortic disorders may have been included.
On the long-term adverse aortic outcome, defined as increased aortic root growth, 
the need for aortic surgery and aortic dissection was observed in two studies [72, 
74]. Increased aortic root growth seemed more pronounced when the initial aortic 
97 women
149 pregnancies
5 AoR
repair1 
107 AoR
<40mm 
42 AoR
≥40mm 
2 type B
dissection2
2 moderate AR 
1 type B dissection
1 type A dissection
1 severe AR3
During
pregnancy 
1 type B dissection 
Fig. 12.3 Cardiovascular outcome in MFS women during pregnancy (Data pooled from [72, 74–
76]). 1Two women with valve sparing surgery, three women with Bentall of which two after acute 
type A dissection, and 2two women with previous type A dissection 3needing AoR replacement 6 
months after pregnancy
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root diameter equaled or exceeded 40 mm. Additionally, the study by Donnelly and 
colleagues showed increased adverse aortic outcome (defined as a composite of 
death, aortic dissection, the need for acute aortic surgery, and a severe symptomatic 
aortic regurgitation) in the parous versus nulliparous group. In multivariate analysis 
the initial aortic root diameter and the rate of aortic root growth during pregnancy 
were the principal predictors of long-term adverse outcome [72].
Some aspects in the interpretation of these data need consideration:
 1. Some women included in these studies may actually have a genetically different 
diagnosis from MFS, as reflected by some unusual clinical features (carotid 
artery dissection is an uncommon feature in MFS, and type B aortic dissection 
occurs more frequently in other H-TAD entities).
 2. The “comparison” group cannot be strictly considered a “control” group, because 
of occult biases in why those patients may have elected not to have any 
pregnancy.
Reports on pregnancy-related complications in MFS have obviously mainly 
focused on the aorta, but other notable risks include cardiac arrhythmias and venous 
thromboembolism (with respective OR of 10.64 and 5.25)  and as reported in a 
retrospective analysis in 339 deliveries to women with MFS [77].
Overall, these studies indicate that in women known with a diagnosis of MFS 
and undergoing appropriate multidisciplinary care before, during, and after preg-
nancy, outcome of pregnancy on the short term is acceptable. Women contemplating 
pregnancy should be properly counseled about the associated risks before 
pregnancy.
12.2.4  Loeys–Dietz Syndrome
Loeys–Dietz syndrome (LDS) is caused by mutations in the genes encoding recep-
tors for TGFβ (TGFBR1 and TGFBR2) and is clinically characterized by more gen-
eralized aortic aneurysms and involvement of branching vessels in association with 
some distinctive dysmorphic features (hypertelorism, bifid uvula) along with some 
systemic features that show overlap with MFS (pectus deformities, scoliosis)[25]. 
The first retrospective study of 21 pregnancies reported four aortic dissections and 
two uterine ruptures in patients with LDS. These women were not diagnosed with 
LDS prior to pregnancy and, hence, did not receive proper management [26]. A 
subsequent report by Attias and colleagues comparing patients with TGFBR2 muta-
tions to patients with FBN1 mutations did not find significant differences between 
the two cohorts. Of the 39 pregnancies occurring among 17 women in the TGFBR2 
cohort, one patient experienced sudden death in the immediate postpartum period 
(no diagnosis was made at that time). No aortic complications were reported during 
pregnancy or postpartum in the others. Among 87 women in the FBN1 cohort, 217 
pregnancies occurred. Four of these patients presented with aortic dissection or 
death during pregnancy (p = 1) [78].
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Prospective studies are currently ongoing, one of which is the data collection by 
the Montalcino Aortic Consortium (MAC) – data on 316 pregnancies in 122 women 
indicate that the risk for aortic dissection is low (five dissections reported) and 
mainly occurred in women who were unaware of the diagnosis and hence did not 
receive proper care at the time of their pregnancy. Women with more pronounced 
systemic features seem to be at an increased risk (G. Jondeau et al. 2016 unpub-
lished data).
12.2.5  Aneurysm Osteoarthritis Syndrome
So far, no data on pregnancy-related complications in patients harboring mutations in 
the SMAD3 gene have been reported. In 1 retrospective series of 23 pregnancies in 13 
women harboring a mutation in the SMAD3 gene, no vascular complications or uter-
ine ruptures were reported. One patient suffered a postpartum hemorrhage [29]. As is 
the case with LDS, prospective data collection is ongoing and results are awaited.
12.2.6  Vascular Ehlers–Danlos Syndrome
Patients with vascular Ehlers–Danlos syndrome (vEDS) are characterized by exten-
sive vascular fragility and may present arterial dissection without preceding dilata-
tion. Management is challenging since imaging studies may not predict events. 
Results from a randomized trial with celiprolol showed a significant reduction in 
vascular events in the treated group [79]. vEDS is caused by mutations in the 
COL3A1 gene. Although the disease primarily affects major branching vessels of 
the aorta, the aorta itself may also be involved. In addition to these vascular compli-
cations, vEDS patients are also at risk for developing uterine rupture during preg-
nancy. Initial reports mentioned increased maternal mortality per pregnancy, ranging 
from 4.3 % to 25 % [21, 80, 81]. A more recent study, however, indicated that 
women with previous pregnancies did not have increased long-term mortality when 
compared to nulliparous women with vEDS [82]. The pregnancy-related death rate 
observed in this study covering 256 pregnancies in vEDS was 5.3 %. Based on these 
recent observations, counseling policies in women with vEDS have shifted from 
strongly discouraging pregnancy to a more nuanced vision with careful prepreg-
nancy counseling of the couple addressing the risks as well as long-term prognosis 
in vEDS. In case of an affected child, there is an increased risk for premature rup-
ture of the membranes due to their intrinsic fragility [83].
12.2.7  Other H-TADs
The outcome of pregnancy in women harboring mutations in the ACTA2 gene has 
been reported in one study [84]. Fifty-three women having a total of 137 pregnan-
cies were included. Of these, eight had aortic dissections in the third trimester or the 
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postpartum period (6 % of pregnancies). Notably, one woman also had a myocardial 
infarct during pregnancy that was independent of her aortic dissection, indicating 
that patients with ACTA2 mutations are also prone to cardiovascular disease outside 
the aorta. Assuming a population-based frequency of peripartum aortic dissections 
of 0.6 %, the rate of peripartum aortic dissections in women with ACTA2 mutations 
is significantly increased (8 out of 39; 20 %). Six of these reported dissections were 
Stanford type A dissections; three were fatal. Three women had ascending aortic 
dissections at diameters less that 5.0 cm (range 3.8–4.7 cm). Importantly, five out of 
the six women presenting with aortic dissection had hypertension, either during or 
before their pregnancy, indicating the importance of proper treatment.
In most of the other syndromic as well as in the vast majority of nonsyndromic 
H-TAD entities, very little or no data specifically related to pregnancy are available, 
and therefore, the recommendations are largely based on the knowledge obtained in 
MFS.
12.2.8  Turner Syndrome
Turner syndrome (TS) is a genetic sex chromosome disorder affecting approxi-
mately 1 in 2,000 live-born females, resulting from complete or partial absence of 
the X chromosome. The phenotype is highly variable and includes short stature, 
dysmorphic features, cardiovascular malformations, premature ovarian failure, and 
predisposition to autoimmune diseases. Different karyotype anomalies may lead to 
development of the syndrome, with or without cell line mosaicism, explaining part 
of the heterogeneity of clinical features. Monosomy X (45,X) has been associated 
with an increased risk of cardiac congenital anomalies [85].
Congenital cardiovascular anomalies can be divided into two main categories: 
aortic valve (mainly BAV) and thoracic vascular abnormalities (aortic coarctation 
and other arch anomalies) [85, 86].
With increasing age, the importance and impact of acquired cardiovascular dis-
ease on morbidity and mortality in Turner patients increase exponentially. A signifi-
cant proportion will develop aortic dilation, ranging from 13 to 37 % in MRI studies, 
depending on the age group and measurement level along the aorta [85, 87]. Due to 
the short stature of Turner women, aortic diameters should be interpreted after cor-
rection for BSA. The BSA-normalized aortic diameter is termed aortic size index 
(ASI). An ASI above 20 mm/m2 is considered abnormal [88]. Excess cardiovascular 
mortality in TS is mainly due to ischemic heart disease, cerebrovascular disease, 
and aortic disease [85]. Aortic dissection is an important cause of early mortality, 
affecting Turner women mostly during the third and fourth decade of life (median 
age 35). The incidence is up to 100-fold increased compared to the general popula-
tion, with a lifelong risk estimated at 1.4 % [88, 89]. Stanford type A aortic dissec-
tion is seen in about two-third of cases, compared to one-third of type B. Risk 
factors for aortic dissection in Turner patients are not well defined. The current 
acknowledged risk markers are mainly based on case reports and a registry-based 
surveys: aortic dilation, bicuspid aortic valve, aortic coarctation, karyotype 45,X, 
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and hypertension [85, 90]. One prospective MRI-based study confirmed the predic-
tive value of aortic dilation, with a high dissection rate in those with an ASI above 
25 mm/m2 [88].
More recently, pregnancy has been recognized as a predisposing condition for aortic 
dissection in TS women, especially in the context of assisted reproductive technologies 
(ART) [91]. This aspect is important given the low rate of spontaneous pregnancy in TS 
women (2–7 %), mainly occurring in women with a mosaic karyotype [92, 93]. Most of 
the other pregnancies in TS are achieved through oocyte donation. Pregnancy-associated 
hypertensive disorders, including preeclampsia and gestational hypertension, are a 
major concern after oocyte donation in the general population (general incidence 
16–40 %). This figure may rise up to 35–38 % in TS women [94, 95].
Since the late 1990s, several worrying case reports have been published on unex-
pected acute aortic dissection in pregnant TS women with a high maternal mortality 
rate (75 %) [94]. Aortic dissections occurred mainly during the third trimester and the 
early postpartum period, probably associated with the higher hemodynamic impact 
of pregnancy. Underlying congenital and acquired cardiovascular anomalies includ-
ing BAV, coarctation of the aorta, or aortic dilation were present in the majority of 
published cases. However, aortic dissection may also occur in the absence of any of 
these. Half of the affected patients were known to have hypertension. Following 
these reports several national and international multicenter retrospective surveys 
were conducted in ART centers to determine the pregnancy outcome after oocyte 
donation in Turner patients, revealing an increased maternal mortality rate around 
2 % related to acute aortic syndromes [94–96]. Strikingly, less than half of Turner 
patients underwent cardiovascular screening before entering the OD program and 
only a quarter of them received echocardiographic follow-up during pregnancy.
12.3  Management
Management of women at risk for aortic complications during pregnancy requires a 
multidisciplinary approach at a tertiary center involving cardiologists, obstetricians, 
anesthesiologists, and medical geneticists.
Management of patients known to have aortic disease mainly consists of strict 
follow-up with aortic imaging, medical treatment aimed at reducing aortic wall 
stress, and prophylactic aortic surgery when indicated. Essentially, these strategies 
do not change in case of pregnancy, with the exception of the frequency of imaging 
and adjustment of the medical treatment in some cases.
Adequate and timely diagnosis of predisposing conditions, as well as prepreg-
nancy counseling, and appropriate follow-up of patients at risk for an aortic event are 
essential to prevent fatal maternal and fetal outcome. In this section, we will discuss 
the different aspects of prevention of aortic dissection and rupture during pregnancy.
Strict and frequent follow-up of women with aortic aneurysms during pregnancy 
is the cornerstone of prevention of aortic dissection. Women with known aortopathy 
should be referred to a tertiary center for follow-up during pregnancy and manage-
ment of delivery [97]. Regular echocardiographic follow-up should be scheduled 
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every 4–8 weeks during pregnancy and up to 6 months’ postpartum. For those 
women with a dilated distal ascending aorta, aortic arch, or descending aorta, fol-
low- up with MRI without gadolinium is recommended during pregnancy [55]. 
Careful blood pressure monitoring and treatment of hypertension is mandatory in 
all of these women.
12.3.1  Medical Treatment
No  randomized drug trials in pregnant women with aortic disease has been per-
formed, and nor does it seem likely that one would ever be performed; hence, treat-
ment recommendations have been extrapolated from nonpregnant cohorts. Much, if 
not most, evidence for medical treatment of aortic disease is derived from studies in 
MFS. Finding a drug capable of arresting aortic root growth is considered the ulti-
mate goal in the medical management of aortic disease in MFS, and for a while, 
hopes were raised for losartan, based on spectacular results in a mouse model for 
MFS [98]. Unfortunately, similar results could not be reproduced in humans, as has 
been demonstrated by several large-scale trials published recently [99–101]. Based 
on these results, slowing the rate of growth is the best we can offer, and beta- 
blockade remains the mainstay of treatment in MFS. Losartan can be considered as 
an alternative for those intolerant for beta-blockers, but not in pregnancy!
In the prospective studies of pregnancy in MFS, mentioned in more detail above, 
the use of beta-blockers varied with about one-third of the patients being treated in 
the studies from Rossiter, Donnelly, and Meijboom, and all but one patient receiving 
treatment in the French study. That one patient not receiving treatment presented 
with aortic dissection [72, 74–76]. These data provide the evidence that supports the 
recommendation that beta-blockade should be used throughout pregnancy in 
patients with aortic disease. Issues with birth defects occurring more frequently 
with the use of certain beta-blockers (Table 12.2) led us to avoid those agents and 
start or switch patients to either metoprolol or labetalol, but fetal growth restriction 
has been demonstrated with the use of beta-blockers in MFS [72] as well as in 
hypertension [102] and congenital heart disease [103], and, therefore, patients 
should be counseled about this risk before conception. Celiprolol, used for the pre-
vention of vascular complications in vEDS, is not reported to affect fetal outcome 
[104]. In women with ACTA2 mutations, blood pressure should be carefully moni-
tored, and treatment with beta-blockers considered [84].
An overview of the effect of drugs on pregnancy and lactation of the various 
drugs mentioned is provided in Table 12.2.
12.3.2  Aortic Surgery
As is the case outside pregnancy, the operative risk associated with thoracic aortic 
surgery is highly dependent on the setting, being much higher in emergency settings 
when compared to elective procedures [105, 106]. In well-prepared circumstances, 
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with optimal perioperative care, including both maternal and fetal monitoring, the 
maternal risk may be reduced to a minimum [107], but the risk of fetal demise 
remains high. Aortic surgery during pregnancy is not only associated with a high 
fetal mortality but also with late neurological impairment in 3–6 % of the children 
[108]; therefore, it should only be considered if medical treatment cannot control 
progression of aortic dilation and/or the life of the mother is in danger. The optimal 
period for surgery is between the 13th and 28th week of pregnancy. When the ges-
tational age reaches 28 weeks, it may be better to deliver the baby by  C-section, and 
arrange the aortic surgery afterwards [55].
Table 12.2 Effect of drugs used during pregnancy in women with aortic disease
Drug
Risk cat. 
(FDA)
Placental 
passage Breast milk passage Fetal risks
Atenolol D Yes Yes Suggested association with 
hypospadias and retroperitoneal 
fibromatosis
Saver alternative 
recommended
IUGR
Fetal bradycardia
Bisoprolol C Yes Yes IUGR as a beta-blocker although 
the use in pregnancy has not been 
studied
Unknown long-term 
effect
Fetal bradycardia
Labetalol C Yes Yes Suggested association with 
congenital anomalies
Compatible with 
breastfeeding
IUGR
Fetal bradycardia
Metoprolol C Yes Yes Not teratogenic but causes fetal 
loss at high doses
Compatible with 
breastfeeding
No association with congenital 
malformations
IUGR
Fetal bradycardia
Propranolol C Yes Yes Suggested association with 
cardiovascular defects and 
hypospadias
Compatible with 
breastfeeding
IUGR
Fetal bradycardia, hypoglycemia, 
polycythemia, thrombocytopenia, 
and hyperbilirubinemia
Celiprolol NAa Yesb Yes Safety in humans has not been 
established
Unknown effect Data from animal studies do not 
indicate harmful direct or indirect 
effectsc
FDA US Food and Drug Administration, IUGR intrauterine growth retardation
aCurrently not approved by the FDA. Under revision for treatment of vEDS
bKofahl Eur J Clin Pharmacol 1993
cwww.medicines.org.uk
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12.3.3  Delivery
Delivery in women with aortic disease should take place at a tertiary center with a car-
diothoracic surgery unit available. The decision on the most appropriate location for the 
delivery should be made on an individual basis. In a woman at high risk of complica-
tions, the delivery should be performed in the cardiothoracic operating room [97].
Cervical ripening using either prostaglandins or mechanical methods and induc-
tion of labor with oxytocin are relatively safe in most women with cardiac disease, 
although there are no specific data on patients with aortic disease [103]. Vaginal 
delivery is restricted to low-risk patients with an aortic diameter below 40 mm. To 
reduce hemodynamic stress, adequate pain relief through epidural anesthesia is 
required, the second stage of labor should be reduced, and vacuum extraction or a 
low-forceps delivery may be required [109, 110]. Regarding epidural anesthesia, 
prior scoliosis surgery and dural ectasia should be taken into account, especially in 
MFS patients. Up to 70 % of patients with MFS have spinal deformations and should 
be assessed by anesthetist in the combined clinic [111]. Higher doses of anesthetics 
may be needed and extra care should be taken to avoid dural taps. If difficulties in 
siting the epidural catheter are anticipated, then an elective  C-section should be 
considered [112]. A small retrospective study on the anesthetic management of MFS 
women did not show that general anesthesia was superior to spinal/epidural anesthe-
sia. Vasoactive drugs (ephedrine, noradrenaline) as well as potentially hypertensive 
drugs (e.g., Methergine) should be avoided [109]. Predelivery counseling by an 
experienced anesthetist is strongly recommended in these patients [112]. There are 
no large-scale trials on the optimal mode of delivery in women with aortic diameters 
>40 mm. Expert consensus, as reported in the European guidelines, gives a class IIa 
indication for vaginal delivery and IIb for C-section when the aorta is between 40 and 
45 mm.  C-section is recommended if the aortic diameter is >45 mm [55].
12.3.4  Breastfeeding and Postdelivery Care
The risk for aortic dissection remains increased up to 6 months after delivery, and 
women should remain under strict surveillance during that period. Imaging of the 
aorta 6 weeks after delivery is recommended. Beta-blockers, angiotensin- converting 
enzyme (ACE) inhibitors, and angiotensin receptor blockers can be used safely dur-
ing breastfeeding.
12.3.5  Obstetrical and Fetal Outcome
In addition to the cardiovascular risks associated with pregnancy in H-TAD and TS, 
obstetric complications and impaired neonatal outcome also need to be taken into 
account in the counseling and management of these patients.
Obstetric complications in patients with MFS are widely reported, mostly in ret-
rospective series. Initial reports on pregnancy in MFS patients by Pyeritz and 
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colleagues described a higher rate of spontaneous abortion (21 %) and preterm labor 
(12 %) when compared to controls [66]. The reported rate of spontaneous abortions 
in MFS patients in subsequent studies varies between 12 and 18 %, which does not 
seem to be much higher than the average population risk of 13 % [69, 75, 113, 114]. 
Preterm labor, related to premature rupture of membranes and cervical incompe-
tence, does appear to occur more frequently in MFS women in some studies, with 
figures varying between 5 and 12 % [66, 113, 114] and an odds ratio of 2.15 reported 
in one series [77]. Other studies however did not confirm an increased risk for pre-
term labor [70, 75], once again indicating the need for prospective large-scale trials.
Adverse neonatal outcomes are related to prematurity and fetal growth restric-
tions in 5–11 % of newborns [66, 70, 72, 113]. The latter observation was shown to 
be associated with a higher rate of beta-blocker usage in the study by Donnelly and 
colleagues (28 % vs. 7 %, p = 0.002) [72]. Similar observations with the use of beta- 
blockers during pregnancy have been reported in women with hypertension and 
congenital heart disease and are thought to be related to a decreased mean arterial 
blood pressure [102, 103, 115]. On the other hand, small-for-gestational-age babies 
were reported with a higher frequency in one study in MFS patients that were not 
treated with beta-blockers [70], indicating that factors other than the beta-blockers 
could also contribute to this finding.
Reports on obstetric complications and fetal outcome in other H-TAD entities 
are scarce. A higher incidence of fatal uterine rupture in patients with LDS and 
vEDS has been reported in initial studies [21, 26], but this seemed to occur less 
frequently in subsequent series of both diseases with two nonfatal uterine ruptures 
in the large vEDS series reported by Murray [82] and no cases of uterine rupture in 
the large series of 316 pregnancies in LDS by Jondeau (G. Jondeau et al. 2016 
unpublished data). Women pregnant with a child affected with vEDS have a higher 
risk of premature rupture of the membranes due to its intrinsic fragility [83].
Delivery through  C-section is needed in the majority of TS pregnancies, due to 
cephalopelvic disproportion or hypertensive complications. A recent study in three 
Nordic countries showed reassuring data on neonatal outcome in singletons, with 
reported incidences of low birthweight (8,8 %), preterm birth (8 %), and major birth 
defects (3.8 %) comparable to conventional in vitro fertilization results. A nation-
wide French study including all ART centers however reported a higher percentage 
of prematurity (38 %) [94]. Twin pregnancies seem to carry a higher risk, and there-
fore single embryo transfer is currently recommended. A review of the literature 
found up to 36 % fetal death (spontaneous abortions or perinatal death) and 20 % 
rate of malformations (either TS or Down syndrome) [92].
12.4  The Effect of Pregnancy Adaptations
Two major concerns arise when addressing the effect of pregnancy on the aorta:
 1. Growth of a known aneurysm
 2. Risk of aortic dissection
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The effect of pregnancy on the aorta is conventionally considered to be threefold 
[116–118]:
(1) Due to the increased cardiac output required for adequate placental perfusion, 
wall shear stress in the aorta will increase; (2) the hormonal changes inherent to 
pregnancy and aimed at softening tissues in preparation for delivery will also affect 
the elastic fibers in the aortic wall, leading to increased fragility; (3) in later stages 
of pregnancy, compression of the lower aorta and iliac arteries by the uterus will 
induce increased outflow resistance in the arterial tree.
The exact contribution and final impact of these changes on the aorta is however 
not fully elucidated, and some features remain to be confirmed in the clinical set-
ting. For example, the impact of 17β-estradiol and progesterone has only been dem-
onstrated in vitro, showing an increase of elastin and fibrillin 1 and a decrease in 
collagen deposition in aortic VSMC when exposed to these hormones [119]. Clinical 
studies show contradictory results, and the effect of estrogens and progesterone on 
arterial stiffness, especially during the third trimester, still needs to be clarified [120, 
121]. What has been established is that the diameter of the aortic root increases 
significantly (1.2 mm on average) over the course of normal pregnancy and remains 
enlarged up to 6 weeks after pregnancy, even in normotensive women [122]. It is 
assumed that while these effects are largely ignorable in healthy women, their 
impact on an underlying diseased aorta may have severe consequences as is 
reflected, for example, in an adverse immediate and long- term aortic outcome in 
patients with Marfan syndrome [72, 74] (see below).
12.5  Preconception Counseling
As already mentioned, pregnancy may increase the risk of aortic dissection and 
progression of aortic disease in women with predisposing condition affecting the 
aorta. Counseling of women with these disorders should tackle the cardiovascular 
and obstetric risks associated with pregnancy and should also address the risk of 
transmission of the disease to the offspring. Cardiovascular and genetic counseling 
should take place during adolescence, ideally during the transition process from 
pediatric to adult cardiology care.
The risk of aortic dissection and the advice towards pregnancy should be dis-
cussed on an individual basis. Since the aorta in most of these women will grow 
over time, postponing pregnancy should be discouraged in some cases. A thorough 
cardiovascular evaluation with careful measurement of aortic diameters prior to 
pregnancy is recommended in all women with underlying aortic conditions. In addi-
tion to cardiac ultrasound, also evaluating valvular and myocardial function, we 
recommend imaging of the entire aorta and branching vessels with CT or MRI scan 
prior to pregnancy [55]. According to the ESC guidelines on the management of 
pregnancy in women with congenital heart disease, an aortic root diameter above 
45 mm in patients with MFS is considered as high risk for dissection during preg-
nancy, and therefore, these women should be strongly advised to avoid pregnancy 
[55]. In addition to the aortic diameter, other factors including aortic growth rate 
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prior to pregnancy and family history of dissection should be taken into account [9, 
72]. In case of vEDS, pregnancy has been regarded as a high-risk situation both for 
cardiovascular and obstetric complications, and therefore, women were counseled 
against pregnancy. However, after the recent publication from Murray et al. in which 
pregnancy in itself did not add further risk of death on the long term [82], the current 
recommendation is to carefully discuss the risk pertaining to pregnancy as well as 
the long-term outcome of the disease on an individual basis. The couple needs to be 
informed of the fact that life expectancy in vEDS is significantly reduced, implying 
that they may not see their child grow into adulthood. Women with TS should also 
undergo detailed cardiovascular evaluation before pregnancy, independent of the 
conception mode (with or without ART), the karyotype, or the presence of mosa-
icism. The check-up should also include accurate blood pressure measurement (ide-
ally by ambulatory blood pressure monitoring). As far as contraindications to 
pregnancy in TS are concerned, the American Society for Reproductive Medicine 
(ASRM) recommendations are the most stringent. Any significant cardiovascular 
abnormality on MRI or an aortic dilation of more than 20 mm/m2 BSA are regarded 
as absolute contraindications for attempting pregnancy [91]. They also state that all 
TS patients should be encouraged to seek alternatives, such as gestational surrogacy 
or adoption, as TS itself should be seen as a relative contraindication. The French 
recommendations include the following listing of contraindications: history of aor-
tic surgery or aortic dissection, aortic dilation above 35 mm or 25 mm/m2 BSA, an 
increase in aortic diameter of more than 10 % confirmed on MRI, and the presence 
of aortic coarctation or uncontrolled hypertension despite treatment. Isolated BAV 
(without aortic dilation) is not considered a contraindication but a risk factor [123]. 
The European Society of Cardiology (ESC) guidelines on the management of car-
diovascular diseases during pregnancy acknowledge the increased risk for aortic 
dissection in TS pregnancies and state that those with aortic dilation are at the high-
est risk [55].
Medical treatment needs to be adjusted prior to conception as some agents, 
including ACE inhibitors and angiotensin receptor blockers, can cause severe 
embryopathy. Ideally, these agents would be switched to safer drugs in the precon-
ception clinic as stopping the treatment as soon as conception takes place risks 
exposing the embryo to teratogenic agents. Beta-blockers are the most commonly 
used drugs in this setting, but may not be entirely safe as their use has been associ-
ated with an increase in fetal malformations. Atenolol can cause fetal malforma-
tions and hypospadias if used during the first trimester and should therefore be 
avoided. Other beta-blockers such as metoprolol, labetalol, and bisoprolol may be 
used safely during pregnancy, although caution with regard to fetal growth is war-
ranted (see above, Table 12.2) [55].
The safety of prophylactic aortic root surgery is a matter of debate. Only five 
cases in women with MFS have been reported so far. No long-term prospective tri-
als have taken place so far, and data from studies conducted in MFS patients indi-
cate that (type B) aortic dissection still occurred in the two women with prior aortic 
root replacement (albeit in the setting of acute dissection) and that two women with 
prior valve sparing aortic root replacement in an elective setting developed 
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significant aortic valve regurgitation through the course of their pregnancy [73]. 
According to the ESC guidelines on pregnancy, prophylactic aortic root surgery is 
recommended in women with MFS when the aortic root diameter exceeds 45 mm; 
the most recent Canadian guidelines on thoracic aortic disease recommend earlier 
prepregnancy surgery at a diameter above 40 mm [55, 124]. This lower threshold is 
also applied in patients with Loeys–Dietz syndrome. Clear guidelines for other 
H-TAD entities are lacking, and the general recommendations are to perform sur-
gery at an aortic root diameter >45 mm. In women with Turner syndrome, an 
indexed aortic diameter of 27 mm/m2 BSA is suggested as a threshold to consider 
prophylactic surgery. It is obvious from these knowledge gaps and discrepancies 
that there is a clear need for more prospective data in larger patient cohorts in order 
to establish the indications and safety of prophylactic aortic root surgery.
Genetic counseling addressing the transmission risk of the disease depends on the 
underlying condition. In this respect, an aspect that tends to be neglected in clinical 
practice is that affected males can equally transmit the disease and should also 
receive proper genetic counseling. MFS and most of the other H-TAD as well as 
vEDS are transmitted as an autosomal dominant trait, resulting in a 50 % chance of 
having an affected child. Inheritance of TS is less well studied. Spontaneous preg-
nancy occurs in only 2 % of the patients with TS [92]. Generally, a transmission risk 
of 25 %, with a higher rate of spontaneous abortions due to monosomy Y, is quoted.
Currently, prenatal diagnosis (PND) and preimplantation diagnosis (PGD) can 
be offered to those patients with a known mutation in most countries. A French 
study indicated that a majority of MFS patients (74 %) was in favor of prenatal test-
ing. The opinion of caregivers varied, but most of them agreed that these issues 
should be addressed in a multidisciplinary team [125].
12.6  Conclusion
In disorders associated with aortic fragility, pregnancy increases the risk of compli-
cations including increased aneurysmal growth, aortic regurgitation, and aortic dis-
section. Key to preventing these complications is the delivery of multidisciplinary 
care by an experienced and knowledgeable team. Prior to pregnancy, appropriate 
counseling should be given, including genetic counseling, and the cardiovascular 
status of the patient examined, allowing treatment to be optimized and changed 
where appropriate.
Data regarding risks, management, and treatment in aortic disease related to preg-
nancy are based on case studies and retrospective analyses; the data are often incon-
sistent possibly because the genetic basis of many of these disorders is only now 
becoming clear, meaning that many of the earlier cohorts were heterogeneous.
Large prospective studies in well-defined cohorts are needed and efforts such as 
the ROPAC study are therefore crucial and very welcome. Future research should be 
focused on the above-mentioned key knowledge gaps in the pathophysiology, man-
agement, and treatment of pregnant patients with aortic disease, including but not 
limited to:
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• Prospective assessment of aortic and obstetric outcome in well-defined homog-
enous cohorts of patients with different types of H-TAD and TS
• Study of the correlation between beta-blocker use and aortic outcome and fetal 
growth in patients with various types of H-TAD
• Prospective assessment of the safety of prepregnancy aortic root replacement
Key Messages
• Pregnancy may increase the risk of aortic dissection in women with under-
lying aortic disease.
• Management of pregnancy in women with aortic disease requires a multi-
disciplinary approach, involving cardiologists, obstetricians, anesthetists, 
and clinical geneticists.
• Individualized prepregnancy counseling on a case-by-case basis address-
ing cardiovascular and obstetric risks is essential.
• Genetic counseling addressing the transmission risk is equally important 
(in women and men).
• Appropriate follow-up with cardiovascular imaging before and during 
pregnancy is the cornerstone of prevention of aortic dissection in pregnant 
women with aneurysms. Follow-up intervals depend on the underlying 
condition and prepregnancy status and should also cover a 6-month post-
partum period.
• In patients with MFS, it is safe to consider pregnancy when the aortic 
diameter is 40 mm or less.
• Medical treatment with beta-blockers during pregnancy should be encour-
aged in patients with MFS and in all other conditions if hypertension is 
present. The patient should be informed about the potential fetal impact.
• Medical treatment with angiotensin receptor blockers and ACE inhibitor is 
contraindicated during pregnancy.
• Recommendations regarding prophylactic aortic root surgery are inconsis-
tent. Surgical replacement before pregnancy is generally recommended if 
the aortic root is above 45 mm in patients with MFS and above 27 mm/m2 
in patients with TS. Lower thresholds of 400–45 mm may be considered in 
women with LDS or in women with MFS and a positive family history for 
dissection or a rapid growth rate. Very limited data regarding safety of 
pregnancy after this procedure are available.
• In women with aortic diameters between 40 and 45 mm, delivery with 
C-section should be considered, and in women with aortic diameters >45 
mm,  C-section is advised.
• In patients with short stature, thoracic aortic diameters must be evaluated 
in relation to body surface area.
• Surgical treatment during pregnancy carries an important risk for the 
mother and fetus and should only be performed in life-threatening circum-
stances.  C-section is recommended after 28th week of pregnancy before 
aortic surgical treatment.
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